HOME >> MEDICINE >> NEWS
Drug-eluting stent controversy explored in the American Heart Hospital Journal

Shelton, Conn. - August 08, 2007 The Summer 2007 issue of The American Heart Hospital Journal explores one of the pivotal issues in cardiology today, the drug-eluting stent (DES). Through commentaries from ten leading national and international specialists, the issue presents a comprehensive discussion on the explosive growth and the potential risks of DESs.

The issue reports on the initial enthusiasm for drug-eluting stents, the great advances made possible by their use, and explores the significance of the benefits and disadvantages revealed through their high-volume adoption.

Dr. Ulrich Sigwart of University Hospital in Geneva, Switzerland, author of one of the studies, examines the sobering current appraisal of DES use, in contrast to the triumphs of their early success. Subacute stent thrombosis due to incomplete intimal coverage, the formation of blood clots that can occur when the inner layers of blood vessels are not fully treated, remains the Achilles heel of DES use, says Dr. Sigwart. The polymer matrix used for the delivery of drugs, which clearly induces inflammatory responses, may, in part, be responsible for very late thrombosis.

Dr. Renu Virmani and colleagues at the CVPath Institute of Gaithersburg, Maryland base the judgments in their article on the evidence obtained through pathologic studies of patients dying after stent implantation. These data indicate that DESs cause both substantial impairment in arterial healing characterized by lack of complete re-endothlialization (the re-healing of the inner surfaces of vessels after stenting) and persistence of fibrin, a protein that indicates blood clotting, when compared with bare metal stents. This delayed healing is the primary substrate underlying all cases of late DES thrombosis at autopsy.

In contrast, Drs. Williams and Abbott, of Brown Medical School and affiliated with Rhode Island Hospital, note, DESs are a revolutionary advancement in interventional
'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
8-Aug-2007


Page: 1 2

Related medicine news :

1. Drug-eluting and absorbable stents push interventional frontiers
2. Drug-eluting stents outperform radiation treatment for coronary restenosis in bare metal stents
3. Drug-eluting stents may cause allergic reactions
4. Drug-eluting stents successfully treat vein-graft disease
5. SCAI news: Drug-eluting stents prove mettle in heart attack patients
6. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
7. New study counts the economic cost of persistent pain in Australia
8. New biodegradable magnesium stents for coronary arteries
9. Emory University researchers find persistent and severe asthma associated with obesity
10. Persistent smokers may have higher risk to become depressed than never smokers
11. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... recruiting, has been recognized for excellence in employee learning. The Omaha-based company has ... ranks organizations with the most successful employer-sponsored training and development programs worldwide. Rankings ...
(Date:12/6/2019)... ... December 06, 2019 , ... Allegheny Health Network (AHN) ... Gyure, who joined AHN from WVU Medicine in May 2018, previously served as AHN’s ... served as interim chair since October and is also part of the pathology faculty ...
(Date:12/6/2019)... ... December 06, 2019 , ... TIME For Kids (TFK) revealed the ... educational, innovative, and fun destinations that are tailored to the interests of kids. The ... , To assemble the list, TIME for Kids gathered nominations from its network of ...
(Date:12/5/2019)... Conn. (PRWEB) , ... December 05, 2019 , ... ... Physician Practice M&A: Risks and Rewards of Building Platforms— on Thursday, December 12, ... are competing for large, multi-specialty medical groups. Middle-market PE firms are scrambling to ...
(Date:12/4/2019)... , ... December 04, 2019 , ... A November 12 ... more cities offer them as public transit options. The article highlighted the life-changing or ... now confined to a bed to a rider fatality after an incident with a ...
Breaking Medicine News(10 mins):
(Date:12/9/2019)... ... December 09, 2019 , ... American Pharmaceutical Review, ... America has released its documentary on " Making Data Work: Leveraging Data for ... companies are currently using data to produce products, and how they can leverage ...
(Date:12/9/2019)... N.Y. (PRWEB) , ... December 09, 2019 , ... ... “The cysts most people contend with are not ‘sebaceous,’” notes Dr. Robert Levine, ... are usually epidermoid – also called ‘epidermal’ – cysts, which have their own ...
(Date:12/8/2019)... ... December 07, 2019 , ... ... affairs, regulatory, and technology-enabled solutions, announced that MAIA Pharmaceuticals, Inc. (MAIA), a specialty ... has chosen Soterius and its partners in Europe, to support their regulatory strategy ...
Breaking Medicine Technology:
Cached News: